B. Riley Financial Issues Positive Forecast for Theravance Biopharma (NASDAQ:TBPH) Stock Price

Theravance Biopharma (NASDAQ:TBPH) had its price objective increased by B. Riley Financial from $14.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the company. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, March 24th. BTIG Research reissued a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. HC Wainwright increased their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. TD Cowen increased their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a report on Monday, March 23rd. Finally, Wall Street Zen lowered shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.83.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $16.56 on Tuesday. The stock’s 50-day simple moving average is $16.91 and its 200-day simple moving average is $17.02. The firm has a market capitalization of $852.72 million, a PE ratio of 8.16 and a beta of 0.17. Theravance Biopharma has a fifty-two week low of $8.09 and a fifty-two week high of $21.03.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president directly owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its holdings in Theravance Biopharma by 51.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 1,408 shares during the period. Pacer Advisors Inc. acquired a new stake in Theravance Biopharma during the fourth quarter worth about $6,342,000. Invesco Ltd. grew its holdings in Theravance Biopharma by 622.2% during the fourth quarter. Invesco Ltd. now owns 177,946 shares of the biopharmaceutical company’s stock worth $3,329,000 after acquiring an additional 153,306 shares during the period. Mackenzie Financial Corp acquired a new stake in Theravance Biopharma during the fourth quarter worth about $705,000. Finally, Susquehanna Portfolio Strategies LLC grew its holdings in Theravance Biopharma by 208.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 43,350 shares of the biopharmaceutical company’s stock worth $811,000 after acquiring an additional 29,313 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.